Major Inclusion Criteria:

          -  Adult subjects; age ≥ 20 years

          -  Histologically or cytological confirmation of a solid, malignant tumor, excluding
             central nervous system (CNS) tumors and lymphoma, that is refractory to standard
             therapy or for which no standard of care regimen currently exists

          -  Patients must have either at least one lesion that can be evaluable using RECIST v1.1
             or patients with mCRPC must have measurable prostate specific antigen above normal
             limits (per local ranges)

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          -  Normotensive or well controlled blood pressure, with or without current
             antihypertensive treatment

          -  Females of child-bearing potential must use 2 highly effective methods of
             contraception

          -  Male patients should be willing to use barrier contraception

        Major Exclusion Criteria:

          -  Any investigational medicinal product or other systemic anticancer treatment within at
             least 4 weeks prior to the first dose of study treatment, or within 8 weeks after
             immunotherapy or other long half-life antibody therapy, whichever is the most
             appropriate and as judged by the Investigator.

          -  Evidence of recent or significant cardiovascular disease

          -  Unresolved toxicities from prior therapy greater than CTCAE Grade 1 at starting study
             treatment

          -  History of seizures, CNS tumors or CNS metastasis

          -  Active or prior documented autoimmune or inflammatory disorders within the past 3
             years to the start of treatment

          -  Patients with prior ≥ Grade3 immune-mediated reactions

          -  Evidence of severe or uncontrolled systemic diseases

          -  Inadequate bone marrow reserve or organ function

          -  Refractory nausea and vomiting, chronic gastrointestinal diseases, or previous
             significant bowel resection that would preclude adequate absorption of AZD4635

          -  History of hypersensitivity to AZD4635 or drugs with a similar chemical structure or
             class to AZD4635

          -  Judgment by the Investigator that the patient should not participate in the study